Procter & Gamble
said studies on a new treatment for an inflammatory bowel disease found that use of the drug led to a significant improvement in patients' overall quality of life.
The delayed-release tablet Asacol is already approved for patients with mildly to moderately active ulcerative colitis to help keep the disease in remission, but it has never before been studied for improvements in quality of life.
Data on the drug, which were presented at a Crohn's and Colitis Foundation national research and clinical conference Friday, showed that the drug led to significant differences in quality of life scores based on an inflammatory bowel disease questionnaire.
"The goals of
ulcerative colitis therapy are to treat active disease and prevent relapse in order to improve quality of life, and now the data tell us that Asacol does, in fact, improve quality of life for patients, as quickly as three weeks from the start of therapy," said E. Jan Irvine, the lead author of the study who's a doctor at St. Michael's Hospital in Toronto.
Shares of P&G dipped 0.4% to $62.55.